Fecal Microbiota Transplantation in Hepatitis B e Antigen-Positive Chronic Hepatitis B Patients: A Pilot Study
Ashish Chauhan, Ramesh Kumar, Sanchit Sharma, Mousumi Mahanta, Sudheer K. Vayuuru, Baibaswata Nayak, Sonu Kumar & Shalimar
Digestive Diseases and Sciences volume 66, pages873–880(2021)Cite this article
307 Accesses
3 Citations
3 Altmetric
Metrics details
Abstract
Background
Intestinal flora plays a critical role in immunity against hepatitis B virus (HBV). Fecal Microbiota Transplantation (FMT) may be a potential immunomodulatory therapy in patients with chronic hepatitis B (CHB).
Aim
We aimed to study role of FMT in hepatitis B e antigen (HBeAg)-positive CHB patients in terms of its effect on HBeAg, HBsAg, and HBV DNA.
Methods
HBeAg-positive patients despite being on antiviral treatment for > 1 year were given six cycles of FMT via gastroscope (nasoduodenal route) at 4 weekly intervals along with antiviral therapy. Twelve out of 14 included patients in FMT arm completed six cycles. Another 15 HBeAg-positive patients who were on oral antivirals for > 1 year were taken as control—antiviral therapy (AVT) arm. Per-protocol analysis was done.
Results
The median (interquartile range) age in the FMT and AVT arm were 29 (25–35) and 29(24–38), respectively (P = 0.794). The median (interquartile range) duration of AVT prior to inclusion in the study was 80 (52–104) and 76 (52–114) months in FMT and AVT arm, respectively (P = 0.884). In the FMT arm, 16.7% (2/12) patients had HBeAg clearance in comparison to none in the AVT arm (P = 0.188). None of the patients in either arm had HBsAg loss. The FMT was tolerated well, 42.8% (6/14) patients reported one or more minor adverse events.
Conclusions
In this non-randomized pilot study, FMT appears to be safe and potentially effective in terms of viral suppression and HBeAg clearance in patients with HBeAg-positive CHB. Further randomized controlled trials are needed in order to obtain robust conclusions.作者: StephenW 时间: 2021-3-6 20:20